Antibody Information

General Information of This Antibody
Antibody ID
ANI0AJTDZ
Antibody Name
PODO447
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1
Antigen Name
Podocalyxin (PODXL)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
PODO447-ADC [Investigative]
 ADC Info 
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 56) High PODXL expression (PODXL+++)
Method Description
MIA PaCa-2 (1x106) or OV3331 (1x106) cells were injected subcutaneously into the right flank of NSG or nude mice. Tumor dimensions were measured twice a week and tumor volumes (cm3) were calculated by. Once tumors reached 0.15cm3, mice were treated with either PODO447- or palivizumab-Vedotin at concentrations ranging from 4 2 mg/kg. ADC treatments were administered intravenously every 4 days.

   Click to Show/Hide
In Vivo Model Pancreas cancer PDX model (PDX: MIA PaCa-2)
References
Ref 1 Targeting a Tumor-Specific Epitope on Podocalyxin Increases Survival in Human Tumor Preclinical Models. Front Oncol. 2022 May 4;12:856424.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.